Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1756-1765

  Robak, Tadeusz ^a   Dmoszynska, Anna ^a   Solal Céligny, Philippe ^a   Warzocha, Krzysztof ^a   Loscertales, Javier ^a   Catalano, John ^a   Afanasiev, Boris V ^a   Larratt, Loree ^a   Geisler, Christian H ^a   Montillo, Marco ^a   Zyuzgin, Ilya ^a   Ganly, Peter S ^a   Dartigeas, Caroline ^a   Rosta, András ^a   Maurer, Jörg ^a   Mendila, Myriam ^a   Saville, M Wayne ^a   Valente, Nancy ^a   Wenger, Michael K ^a   Moiseev, Sergey I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; CHLORAMBUCIL; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; PREDNISOLONE; PREDNISONE; RASBURICASE; RITUXIMAB; VALACICLOVIR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEPATITIS B; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PSYCHOLOGICAL ASPECT; RETREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; QUALITY OF LIFE; RETREATMENT; VIDARABINE;

EID: 77950478885     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4556     Document Type: Article

References (44)

1. Horner MJ, Ries LAG, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. http://seer.cancer.gov/csr/1975- 2006/
2. Sant M, Allemani C, Santaquilani M, et al: EUROCARE-4: Survival of cancer patients diagnosed in 1995-1999 - Results and commentary. Eur J Cancer 45:931-991, 2009
3. Gribben JG: How I treat CLL upfront. Blood 115:187-197, 2010
4. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet 347:1432-1438, 1996 (Pubitemid 26161205)
5. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
6. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
7. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
8. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
9. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003 (Pubitemid 46638587)
10. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001 (Pubitemid 32366970)
11. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001 (Pubitemid 32366969)
12. Mavromatis B, Cheson BD: Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 21:1874-1881, 2003
13. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998 (Pubitemid 28363048)
14. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003 (Pubitemid 36025880)
15. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005 (Pubitemid 40053062)
16. Schulz H, Klein SK, Rehwald U, et al: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100:3115-3120, 2002 (Pubitemid 35217057)
17. Fischer K, Stilgenbauer S, Schweighofer C, et al: Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 110:3106, 2007 (abstr)
18. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006 (Pubitemid 46638781)
19. Robak T, Smolewski P, Cebula B, et al: Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 79:107-113, 2007 (Pubitemid 47063264)
20. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
21. Tam CS, O'Brien S, Wierda W, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
22. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005 (Pubitemid 46211312)
23. Wierda W, O'Brien S, Faderl S, et al: A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106:337-345, 2006 (Pubitemid 43100442)
24. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
25. van der Velden V, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604-611, 2007 (Pubitemid 46444541)
26. Bruggemann M, Droese J, Bolz I, et al: Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 14:1419-1425, 2000 (Pubitemid 30599323)
27. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
28. Rawstron AC, Villamor N, Ritgen M, et al: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956-9564, 2007
29. Hallek M, Fingerle-Rowson G, Fink A, et al: Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 112:325, 2008 (abstr)
30. Tam CS, Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:479-498, 2007 (Pubitemid 47263407)
31. Hillmen P, Pocock C, Cohen D, et al: NCRI CLL201 trial: A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood 110:752, 2007 (abstr)
32. Faderl S, Wierda W, Ferrajoli A, et al: Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 110:627, 2007 (abstr)
33. Wierda WG, O'Brien S, Faderl S, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108:31, 2006 (abstr)
34. Bosch F, Abrisqueta P, Villamor N, et al: Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 27:4578-4584, 2009
35. Lamanna N, Heaney ML, Brentjens RJ, et al: Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): A new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR. Blood 110:3115, 2007 (abstr)
36. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007 (Pubitemid 46105933)
37. Eichhorst BF, Busch C, Duehresen U, et al: CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL Study Group (GCLLSG). Blood 106:2126, 2005 (abstr)
38. Faderl S, Thomas DA, O'Brien S, et al: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415, 2003 (Pubitemid 36857922)
39. Castro JE, Sandoval-Sus JD, Bole J, et al: Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22:2048-2053, 2008
40. Bowen DA, Call TG, Jenkins GD, et al: Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 48:2412-2417, 2007 (Pubitemid 350253473)
41. Tsimberidou AM, Wen S, McLaughlin P, et al: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27:904-910, 2009
42. Berinstein NL, Grillo-López AJ, White CA, et al: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001, 1998 (Pubitemid 28496709)
43. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507-2513, 2003 (Pubitemid 36857605)
44. Eichhorst B, Hallek M, Dreyling M: Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and followup. Ann Oncol 20:iv102-iv104, 2009 (suppl 4)